ReviewInternational journal of pharmaceutical investigation
Application of three-dimensional printing for colon targeted drug delivery systems.
Review in International journal of pharmaceutical investigation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- 3D-Printed core-shell tablet for effective oral delivery of AT-MSC secretome in inflammatory bowel disease therapy.Drug delivery and translational research · 2026Article
- Three-Dimensional Printing for Precision and Personalized Patient Care: A New Paradigm for Pharmacy Practice?Pharmaceutics · 2026Review
- 3D-Printed Multifunctional Multicompartment Polymer-Based Capsules for Tunable and Spatially Controlled Drug Release.Journal of functional biomaterials · 2025Article
- Advances in colon-targeted drug technologies.Current opinion in gastroenterology · 2025Review
- Three-Dimensional Printing of Hydrogel Blend Tissue Engineering Scaffolds with In Situ Delivery of Anticancer Drug for Treating Melanoma Resection-Induced Tissue Defects.Journal of functional biomaterials · 2024Article
- Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2024Review
- Status of Polymer Fused Deposition Modeling (FDM)-Based Three-Dimensional Printing (3DP) in the Pharmaceutical Industry.Polymers · 2024Review
- 3D Printed Personalized Colon-targeted Tablets: A Novel Approach in Ulcerative Colitis Management.Current drug delivery · 2024Review
- Biomedical applications of three-dimensional bioprinted craniofacial tissue engineering.Bioengineering & translational medicine · 2023Review
- 3D Printed Fractal-like Structures with High Percentage of Drug for Zero-Order Colonic Release.Pharmaceutics · 2022Article
- Drug Delivery Applications of Three-Dimensional Printed (3DP) Mesoporous Scaffolds.Pharmaceutics · 2020Review
- Flavonoids fromMedicines (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orally administered solid dosage forms currently dominate over all other dosage forms and routes of administrations. However, human gastrointestinal tract (GIT) poses a number of obstacles to delivery of the drugs to the site of interest and absorption in the GIT. Pharmaceutical scientists worldwide have been interested in colon drug delivery for several decades, not only for the delivery of the drugs for the treatment of colonic diseases such as ulcerative colitis and colon cancer but also for delivery of therapeutic proteins and peptides for systemic absorption. Despite extensive research in the area of colon targeted drug delivery, we have not been able to come up with an effective way of delivering drugs to the colon. The current tablets designed for colon drug release depend on either pH-dependent or time-delayed release formulations. During ulcerative colitis the gastric transit time and colon pH-levels is constantly changing depending on whether the patient is having a relapse or under remission. Hence, the current drug delivery system to the colon is based on one-size-fits-all. Fails to effectively deliver the drugs locally to the colon for colonic diseases and delivery of therapeutic proteins and peptides for systemic absorption from the colon. Hence, to overcome the current issues associated with colon drug delivery, we need to provide the patients with personalized tablets which are specifically designed to match the individual's gastric transit time depending on the disease state. Three-dimensional (3D) printing (3DP) technology is getting cheaper by the day and bespoke manufacturing of 3D-printed tablets could provide the solutions in the form of personalized colon drug delivery system. This review provides a bird's eye view of applications and current advances in pharmaceutical 3DP with emphasis on the development of colon targeted drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.